- Home
- ZYBT vs NBTX Comparison
ZYBT vs NBTX Comparison
Compare ZYBT & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYBT
- NBTX
- Stock Information
- Founded
- ZYBT 2004
- NBTX 2003
- Country
- ZYBT China
- NBTX France
- Employees
- ZYBT N/A
- NBTX N/A
- Industry
- ZYBT
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- ZYBT
- NBTX Health Care
- Exchange
- ZYBT NYSE
- NBTX Nasdaq
- Market Cap
- ZYBT 201.4M
- NBTX 201.9M
- IPO Year
- ZYBT 2025
- NBTX 2020
- Fundamental
- Price
- ZYBT $4.62
- NBTX $3.75
- Analyst Decision
- ZYBT
- NBTX Strong Buy
- Analyst Count
- ZYBT 0
- NBTX 1
- Target Price
- ZYBT N/A
- NBTX $12.00
- AVG Volume (30 Days)
- ZYBT 33.8K
- NBTX 8.9K
- Earning Date
- ZYBT 01-01-0001
- NBTX 09-18-2024
- Dividend Yield
- ZYBT N/A
- NBTX N/A
- EPS Growth
- ZYBT N/A
- NBTX N/A
- EPS
- ZYBT 0.06
- NBTX N/A
- Revenue
- ZYBT $26,111,272.00
- NBTX $45,220,186.00
- Revenue This Year
- ZYBT N/A
- NBTX N/A
- Revenue Next Year
- ZYBT N/A
- NBTX N/A
- P/E Ratio
- ZYBT $75.57
- NBTX N/A
- Revenue Growth
- ZYBT N/A
- NBTX 526.17
- 52 Week Low
- ZYBT $3.70
- NBTX $2.76
- 52 Week High
- ZYBT $6.10
- NBTX $7.51
- Technical
- Relative Strength Index (RSI)
- ZYBT N/A
- NBTX 53.25
- Support Level
- ZYBT N/A
- NBTX $3.60
- Resistance Level
- ZYBT N/A
- NBTX $3.95
- Average True Range (ATR)
- ZYBT 0.00
- NBTX 0.19
- MACD
- ZYBT 0.00
- NBTX -0.01
- Stochastic Oscillator
- ZYBT 0.00
- NBTX 38.18
About ZYBT ZHENGYE BIOTECHNOLOGY HLDG LTD
Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs and is available in 29 provincial regions across China and are exported overseas to Vietnam, Pakistan and Egypt.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.